How to compare the studies
Start with the exact substance. A blend needs evidence about the blend. A peptide fragment needs evidence about that fragment. GHK without copper and GHK-Cu are related but distinct forms. These details can determine whether a paper addresses the claim beside it.
Next identify who or what was studied. Cells in a dish can reveal a pathway. An animal model can test repair in a living system. A human study can investigate outcomes in people, but its size, comparison group, and follow-up still limit the conclusion. The category alone does not establish the quality of the study.
The route also matters. A topical preparation, an intravenous preparation, and an animal experiment using another route create different exposures. Results cannot move freely between them. Finally, check the outcome: a change in a marker is different from stronger tissue, less pain, or restored function.
BPC-157 and tissue repair
The 2003 rat Achilles experiment examined mechanical and functional healing after a tendon was cut. That gives the finding a direct relationship to tendon repair in that model. The missing step is a suitable human comparison addressing the same practical question.
The 2025 intravenous pilot addressed short-term safety in two healthy adults. It did not test tendon recovery. Adding a human safety observation to an animal healing experiment does not create a human healing trial. Each result answers its own question.
The 2025 BPC-157 review describes the limited human record alongside the larger animal literature. The review is useful context for a claim, particularly when the claim gives no indication that the main healing evidence comes from animals.
TB-500 and the longer protein
The rat wound study from 1999 used full-length thymosin beta-4. So did the early safety study in forty healthy volunteers. TB-500 is a shorter, chemically capped fragment of that protein.
The identity gap comes before questions about how well a trial was designed. Even a strong study of the full protein cannot establish the fragment's effect. The FDA assessment of TB-500-related substances is especially useful for checking which substance was actually tested in the cited literature.
GHK-Cu and topical outcomes
Small skin studies are closer to cosmetic questions than to sports-injury recovery. The 2025 topical GHK review discusses both the limited clinical evidence and the challenge of delivery through skin. A topical observation does not establish a systemic treatment effect.
The 2016 hair trial adds another distinction: it used GHK without copper in combination with another active ingredient. Its result cannot be credited entirely to GHK-Cu. Study participants, preparation, route, and outcome all need to remain visible when the result is summarized.
KLOW adds a combination question
KLOW combines four ingredients with different research histories. A proposed rationale links inflammatory signaling, blood supply, tissue structure, and cell movement. Those separate mechanisms do not establish how the complete mixture behaves in people.
There is no controlled blend result among the studies cited here that would support a ranking above the individual compounds. An additional ingredient can change exposure or risk as well as a proposed benefit. A comparison that simply adds the reported benefits of four ingredients assumes the very result that needs testing.
Comparing safety and status
The 2026 sports-medicine review describes the shortage of rigorous human safety evidence for unapproved peptides. Small studies may miss uncommon harms, delayed effects, or risks in people whose health differs from the study participants'. An absence of reported problems is not a complete safety profile.
FDA's page current as of April 22, 2026 lists several of these ingredients as nominated but withdrawn. This is not clearance or approval. A prescription and drug approval also answer different questions. The questions page discusses these distinctions without supplying a dose or selecting a treatment for an individual.